1 / 17

Update on Influenza surveillance in the U.S., 2006-7 season

VRBPAC Gaithersburg, MD 27-28 February, 2007 Joseph Bresee, MD Chief, Epidemiology and Prevention Branch Influenza Division Centers for Disease Control and Prevention. Update on Influenza surveillance in the U.S., 2006-7 season. CDC’s U.S. Influenza Surveillance System. State and Territorial

ozzie
Download Presentation

Update on Influenza surveillance in the U.S., 2006-7 season

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. VRBPACGaithersburg, MD27-28 February, 2007Joseph Bresee, MDChief, Epidemiology and Prevention BranchInfluenza DivisionCenters for Disease Control and Prevention Update on Influenza surveillance in the U.S., 2006-7 season

  2. CDC’s U.S. Influenza Surveillance System State and Territorial Epidemiologists Population-based Hospitalization Pediatric Mortality Vital Statistics Registrars Sentinel Providers CDC Other Laboratories Health Departments Public Health Officials Public Physicians Media

  3. U.S. Influenza Surveillance: Overview State and Territorial Epidemiologists Population-based Hospitalization Pediatric Mortality Vital Statistics Registrars Sentinel Providers CDC Other Laboratories Health Departments Public Health Officials Public Physicians Media

  4. Visits for Influenza-like Illness Reported by Sentinel Providers, 2006-07 and Previous 2 Seasons

  5. NVSN Influenza Laboratory-Confirmed Cumulative Hospitalization Rates for Children 0 - 4 Years, 2006-07 and Previous 6 Seasons 14 12 10 8 Population-Based Rate per 10,000 Children 6 4 2 0 40-41 42-43 44-45 46-47 48-49 50-51 52 -1 2-3 4-5 6-7 8-9 10-11 12-13 14-15 16-17 2006-2007 Influenza Season 2 Week Reporting Period 2000-2001 2001-2002 2002-2003 2003-2004 2004-2005 2005-2006 2006-2007 Laboratory-confirmed influenza hospitalizations, 0-4 yrs, New Vaccine Surveillance Network

  6. Laboratory-confirmed influenza hospitalizations, Emerging Infections Program

  7. Pneumonia and Influenza Mortalityfor 122 U.S. CitiesWeek Ending 01/20/2007 EpidemicThreshold SeasonalBaseline 2003 2004 2005 2006 10 20 30 40 50 10 20 30 40 50 10 20 30 40 50 10 20 30 40 50 10

  8. Surveillance for Pediatric Deaths Attributed to Influenza Complications • As of February 15, 2007, CDC has received 15 reports of influenza-associated pediatric deaths this season • 10 were 5 years of age or older • Underlying medical conditions • 3 with underlying conditions that might have contributed to severity • 5 with no known underlying conditions • 2 with unknown previous health status • Vaccination status • Unvaccinated (9) • Vaccinated (1 ) • 2004-2005: 44 deaths • 2005-2006: 48 deaths • 2003-2004: 153 deaths

  9. U.S. WHO/NREVSS Collaborating LaboratoriesSummary, 2006-07 10,458 viruses typed 84% A / 16% B 2,439 (28%) subtyped 87% A (H1) 13% A (H3)

  10. Antiviral resistance • High levels of adamantane-resistance identified during 2005* • H1N1 : 2 of 8 (25%) adamantane-resistant • H3N2 : 192 of 209 (92%) adamantane-resistant • Fewer adamantane-resistant isolates in 2006-2007** • Global surveillance • H1N1: 5 of 199 (3%) • H3N2: 24 of 54 (44%) • U.S. isolates • H1N1: 1 of 91 (1%) • H3N2: 3 of 10 (33%) • No resistance to oseltamivir or zanamivir among isolates tested at CDC since 2005 (n=437)** * Bright et al. (2006): JAMA 295; 891-4 ** L Gubareva, CDC, preliminary data

  11. Upcoming issues for ACIP, 2007-8 • New vaccine strains? • Upcoming WHO and VRBPAC, Feb 2007 • Extension of recommendation not to use adamantanes • Persistently high adamantane resistance among H3 viruses • Available alternative • Harmonize AAP and ACIP recs for young children • Children 6 mo - <9 yrs who received a single dose during the first year will be recommended to receive 2 doses the following year • Age groups and risk groups for whom routine vaccination is recommended is not changed compared to 2006 recommendations

  12. Thank you

  13. Milestones in Recommendation Changes 2000: All adults 50 and older 2004: All children aged 6--23 months All women who will be pregnant during influenza season 2005: All persons with any condition that can compromise respiratory function or the handling of respiratory secretions 2006: All children aged 24--59 months and their household contacts and out-of-home caregivers

More Related